Mycosis fungoides natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
==Natural History==
==Natural History==
*The [[Symptom|symptoms]] of mycosis fungoides usually develop in the first nonspecific, [[Indolent ulcer|indolent]] [[Inflammation|inflammatory]] such as : etopic [[dermatitis]], nonspecific [[Chronic (medical)|chronic]] [[dermatitis]], or [[parapsoriasis]] ( large-[[plaque]] [[parapsoriasis]]).<ref name="QuaglinoPimpinelli20123">{{cite journal|last1=Quaglino|first1=Pietro|last2=Pimpinelli|first2=Nicola|last3=Berti|first3=Emilio|last4=Calzavara-Pinton|first4=Piergiacomo|last5=Alfonso Lombardo|first5=Giuseppe|last6=Rupoli|first6=Serena|last7=Alaibac|first7=Mauro|last8=Bottoni|first8=Ugo|last9=Carbone|first9=Angelo|last10=Fava|first10=Paolo|last11=Fimiani|first11=Michele|last12=Mamusa|first12=Angela Maria|last13=Titli|first13=Stefano|last14=Zinzani|first14=Pier Luigi|last15=Bernengo|first15=Maria Grazia|title=Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides|journal=Cancer|volume=118|issue=23|year=2012|pages=5830–5839|issn=0008543X|doi=10.1002/cncr.27627}}</ref>
*The [[Symptom|symptoms]] of mycosis fungoides usually develop in the first nonspecific, [[Indolent ulcer|indolent]] [[Inflammation|inflammatory]] such as : etopic [[dermatitis]], nonspecific [[Chronic (medical)|chronic]] [[dermatitis]], or [[parapsoriasis]] ( large-[[plaque]] [[parapsoriasis]]).<ref name="QuaglinoPimpinelli20123">{{cite journal|last1=Quaglino|first1=Pietro|last2=Pimpinelli|first2=Nicola|last3=Berti|first3=Emilio|last4=Calzavara-Pinton|first4=Piergiacomo|last5=Alfonso Lombardo|first5=Giuseppe|last6=Rupoli|first6=Serena|last7=Alaibac|first7=Mauro|last8=Bottoni|first8=Ugo|last9=Carbone|first9=Angelo|last10=Fava|first10=Paolo|last11=Fimiani|first11=Michele|last12=Mamusa|first12=Angela Maria|last13=Titli|first13=Stefano|last14=Zinzani|first14=Pier Luigi|last15=Bernengo|first15=Maria Grazia|title=Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides|journal=Cancer|volume=118|issue=23|year=2012|pages=5830–5839|issn=0008543X|doi=10.1002/cncr.27627}}</ref>
*The majory of [[Patient|patients]] have early stage (77.9% : IA stage IA 38.8%, stage IB  39.1% ), patietns with satge IIB diagnosed in 5.5% and stage III observed in 6.6%.<ref name="QuaglinoPimpinelli20123" />
*The majory of [[Patient|patients]] have early stage (77.9% : IA stage IA 38.8%, stage IB  39.1% ), [[Patient|patients]] with satge IIB diagnosed in 5.5% and stage III observed in 6.6%.<ref name="QuaglinoPimpinelli20123" />
*The majority of patients of mycosis fungoides are not diagnosed and end stage not be observed.<ref name="QuaglinoPimpinelli20123" />
*The majority of patients of mycosis fungoides are not diagnosed and end stage not be observed.<ref name="QuaglinoPimpinelli20123" />
*Mycosis fungoides in early stage characterized with nonspecific dermatitis or consists patches observed on the lower trunk and buttocks.<ref name="QuaglinoPimpinelli20123" />
*Mycosis fungoides in early stage characterized with nonspecific [[dermatitis]] or consists [[Patched|patches]] observed on the lower [[trunk]] and [[buttocks]].<ref name="QuaglinoPimpinelli20123" />
* Mycosis fungoides is initially an indolent lymphoma that may later develop peripheral lymphadenopathy and can finally progress to widespread visceral involvement.<ref name="radio">Mycosis fungoides. Radiopaedia.http://radiopaedia.org/articles/mycosis-fungoides Accessed on January 20, 2016</ref>
* Mycosis fungoides is initially an [[Indolent ulcer|indolent]] [[lymphoma]] that may later develop peripheral [[lymphadenopathy]] and can finally progress to widespread visceral involvement.<ref name="radio">Mycosis fungoides. Radiopaedia.http://radiopaedia.org/articles/mycosis-fungoides Accessed on January 20, 2016</ref>
* Cutaneous T cell lymphoma is usually initially seen by dermatologists with patients presenting with skin lesions such as erythematous patches or plaque.
* Cutaneous T cell lymphoma is usually initially seen by [[Dermatologist|dermatologists]] with [[Patient|patients]] presenting with [[skin]] [[Lesion|lesions]] such as [[Erythema|erythematous]] [[Patchoulol|patches]] or [[plaque]].
* Patients often have a history of several years of eczematous or dermatitic skin lesions before the diagnosis is finally established.
* [[Patient|Patients]] often have a history of several years of [[Eczema|eczematous]] or [[dermatitis]] [[skin]] [[Lesion|lesions]] before the diagnosis is finally established.
* The skin lesions then progress from the patch stage to the [[plaque]] stage to cutaneous tumors.
* The [[skin]] [[Lesion|lesions]] then progress from the patch stage to the [[plaque]] stage to [[cutaneous]] [[Tumor|tumors]].


==Complications==
==Complications==

Revision as of 19:52, 21 December 2018


Mycosis fungoides Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mycosis Fungoides from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mycosis fungoides natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mycosis fungoides natural history, complications and prognosis

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mycosis fungoides natural history, complications and prognosis

CDC on Mycosis fungoides natural history, complications and prognosis

Mycosis fungoides natural history, complications and prognosis in the news

Blogs on Mycosis fungoides natural history, complications and prognosis

Directions to Hospitals Treating Mycosis fungoides

Risk calculators and risk factors for Mycosis fungoides natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

If left untreated, cutaneous T cell lymphoma may progress to develop cutaneous patches, plaque, and tumors. Depending on the extent of the lymphoma at the time of diagnosis, the prognosis may vary.

Natural History

Complications

  • Common complications of Cutaneous T cell lymphoma include:
    • Mycosis Fungoides increased risk of secondary malignancies such as primary malignancy, especially Hodgkin lymphoma, chronic leukemia, and lung cancer.[3]
    • Neurologic involvement (intracerebral mycosis fungoides)[4]
    • Oral involvement[5]
    • Hypersensitivity reaction with topical HN2 therapy [6]
    • Hypopigmentation or hyperpigmentation of treated areas[7]

Prognosis

  • Cutaneous T cell lymphoma is usually a slow-growing (indolent) lymphoma.[8]
  • The prognosis for people with cutaneous T cell lymphoma is based on the extent of disease and how the person responds to treatment.
  • Although more advanced stages of cutaneous T cell lymphoma may not be cured, the lymphoma can still be controlled with treatment.

Favorable prognosis

Unfavorable prognosis


Staging

  • The staging of cutaneous T cell lymphoma is based on skin and lymph node involvement.[8]
  • Staging for cutaneous T cell lymphoma(Mycosis fungoides (MF) and Sezary syndrome have same critera for staging) is provided in the following table:[9][10]
Staging for mycosis fungoides and Sezary syndrome
Skin (T)
T1 Limited patches, papules, and/or plaques covering <10% of the skin surface. May further stratify into T1a (patch only) versus T1b (plaque patch)
T2 Patches, papules, or plaques covering 10% of the skin surface. May further stratify into T2a (patch only) versus T2b (plaque patch).
T3 One or more tumours (1-cm diameter)
T4 Confluence of erythema covering 80% body surface area
Node (N)
N0 No clinically abnormal peripheral lymph nodes; biopsy not required
N1 Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN0-2
N1a Clone negative
N1b Clone posetive
N2 Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3
N2a Clone negatove
N2b Clone posetive
N3 Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3e4 or NCI LN4; clone positive or negative
NX Clinically abnormal peripheral lymph nodes; no histologic confirmation
Visceral (M)
M0 No visceral organ involvement
M1 Visceral involvement (must have pathology confirmation and organ involved should be specified)
Blood (B)
B0 0 Absence of significant blood involvement: 5% of peripheral blood lymphocytes are atypical (Sezary) cells B0a Clone negative B0b Clone positive
B1 Low blood tumour burden: >5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2 B1a Clone negative B1b Clone positive
B2 High blood tumour burden: 1000/mL Sezary cells with positive clone

The staging of Sezary syndrome is based on the clinical stages:[9][11]

clinical stages
Stage T N M B DDS
IA 1 0 0 0/1 98
IB 2 0 0 0/1 89
IIA 1.2 1.2 0 0/1 89
IIB 3 0-2 0 0/1 56
IIIA 4 0-2 0 0 54
IIIB 4 0-2 0 1 48
IVA1 1-4 0-2 0 2 41
IVA2 1-4 3 0 0-2 23
IVB 1-4 0-3 1 0-2 18
  • [5-year disease free survival (DSS)]
  • Cancer has spread to other organs in the body, including the blood and bone marrow
  • Lymph nodes may be enlarged and may contain cancer

References

  1. 1.0 1.1 1.2 1.3 Quaglino, Pietro; Pimpinelli, Nicola; Berti, Emilio; Calzavara-Pinton, Piergiacomo; Alfonso Lombardo, Giuseppe; Rupoli, Serena; Alaibac, Mauro; Bottoni, Ugo; Carbone, Angelo; Fava, Paolo; Fimiani, Michele; Mamusa, Angela Maria; Titli, Stefano; Zinzani, Pier Luigi; Bernengo, Maria Grazia (2012). "Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides". Cancer. 118 (23): 5830–5839. doi:10.1002/cncr.27627. ISSN 0008-543X.
  2. Mycosis fungoides. Radiopaedia.http://radiopaedia.org/articles/mycosis-fungoides Accessed on January 20, 2016
  3. Cengiz FP, Emiroğlu N, Onsun N (December 2017). "Frequency and Risk Factors for Secondary Malignancies in Patients with Mycosis Fungoides". Turk J Haematol. 34 (4): 378–379. doi:10.4274/tjh.2017.0234. PMC 5774354. PMID 28832009.
  4. Law, Meng; Teicher, Noah; Zagzag, David; Knopp, Edmond A. (2003). "Dynamic contrast enhanced perfusion MRI in mycosis fungoides". Journal of Magnetic Resonance Imaging. 18 (3): 364–367. doi:10.1002/jmri.10361. ISSN 1053-1807.
  5. Bassuner, Juri; Miranda, Roberto N.; Emge, Drew A.; DiCicco, Beau A.; Lewis, Daniel J.; Duvic, Madeleine (2016). "Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene". Case Reports in Dermatological Medicine. 2016: 1–7. doi:10.1155/2016/5857935. ISSN 2090-6463.
  6. Price NM, Hoppe RT, Deneau DG (December 1983). "Ointment-based mechlorethamine treatment for mycosis fungoides". Cancer. 52 (12): 2214–9. PMID 6640491.
  7. Abel EA, Sendagorta E, Hoppe RT (June 1986). "Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides". J. Am. Acad. Dermatol. 14 (6): 1029–38. PMID 3722479.
  8. 8.0 8.1 Cutaneous T cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/cutaneous-t-cell-lymphoma/?region=on Accessed on January 19, 2016
  9. 9.0 9.1 Trautinger, Franz; Eder, Johanna; Assaf, Chalid; Bagot, Martine; Cozzio, Antonio; Dummer, Reinhard; Gniadecki, Robert; Klemke, Claus-Detlev; Ortiz-Romero, Pablo L.; Papadavid, Evangelia; Pimpinelli, Nicola; Quaglino, Pietro; Ranki, Annamari; Scarisbrick, Julia; Stadler, Rudolf; Väkevä, Liisa; Vermeer, Maarten H.; Whittaker, Sean; Willemze, Rein; Knobler, Robert (2017). "European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017". European Journal of Cancer. 77: 57–74. doi:10.1016/j.ejca.2017.02.027. ISSN 0959-8049.
  10. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S (September 2007). "Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)". Blood. 110 (6): 1713–22. doi:10.1182/blood-2007-03-055749. PMID 17540844.
  11. Jawed, Sarah I.; Myskowski, Patricia L.; Horwitz, Steven; Moskowitz, Alison; Querfeld, Christiane (2014). "Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)". Journal of the American Academy of Dermatology. 70 (2): 205.e1–205.e16. doi:10.1016/j.jaad.2013.07.049. ISSN 0190-9622.


Template:WikiDoc Sources